Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01687673 · ClinicalTrials.gov registry record · Phase 2
Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT01687673 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 29 participants.
The verdict
NCT01687673, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
This Phase II trial is being developed following the completion of a Phase I study of the combination of temsirolimus and sorafenib in 25 first-line therapy patients with advanced hepatocellular carcinoma (December 2009 through April 2012). The maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of the combination of temsirolimus is 10 mg IV weekly plus sorafenib 200 mg (oral, twice daily).
Interventions
- DRUG Temsirolimus
- DRUG Sorafenib:
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2012-10-05 |
| Est. Completion | 2020-01-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01687673
The ClinicalTrials.gov registry entry for NCT01687673 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Temsirolimus is the first listed.
NCT01687673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01687673 about?
NCT01687673 is a clinical study titled "Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma". This Phase II trial is being developed following the completion of a Phase I study of the combination of temsirolimus and sorafenib in 25 first-line therapy patients with advanced hepatocellular carcinoma (December 2009 through April 2012). The maximum tolerated dose (MTD) and recommended phase II d...
What is the current status of trial NCT01687673?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2012-10-05. Estimated completion is 2020-01-09.
What interventions are being tested in trial NCT01687673?
The interventions under investigation include: Temsirolimus (DRUG), Sorafenib: (DRUG).
Who is sponsoring clinical trial NCT01687673?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.